Abstract
Estrogen receptor (ER) testing has become an important part of breast cancer reporting as the ER status is a predictor of hormonal treatment efficacy. Progesteron receptors (PR) are often tested in parallel, and the best response to hormonal manipulations can be expected in tumors positive for both receptors. The existence of breast cancers with an ER negative and PR positive phenotype is controversial. A series of cases with this phenotype were reevaluated to clarify the existence and the frequency of this entity. A total of 205/6587 (3.1%; range of the rate per department: 0.3–7.1%.) cases reported to have the ER-negative and PR-positive status by immunohistochemistry were collected from 9 Hungarian departments. After careful reevaluation of the tumor slides and control tissues with a 1% cut-off for positivity and restaining of the questionable cases, all but 1 of the reevaluable 182 cases changed their original phenotype. Most cases converted to dual positives (n = 124) or dual negatives (n = 31) or unassessable / questionable. ER-negative and PR-positive breast cancers are very rare if existing. Such a phenotype should prompt reassessment.
Similar content being viewed by others
Abbreviations
- Ab:
-
antibody
- BF:
-
buffered formaline
- ER:
-
estrogen receptor
- ER−:
-
estrogen receptor-negative
- ER+:
-
estrogen receptor-positive
- HIER:
-
heat induced epitope retrieval
- IC:
-
internal control
- ID:
-
identification
- MoAb:
-
monoclonal antibody
- PR:
-
progesterone receptor
- PR−:
-
progesterone receptor-negative
- PR+:
-
progesterone receptor-positive
- RT:
-
room temperature
- RTU:
-
ready-to-use prediluted antibodies
References
Moshin SK, Weiss H, Havinghurst T et al (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17:1545–1554
Viale G, Regan MM, Maiorano E et al (2008) Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors—International Breast Cancer Study Group. J Clin Oncol 26:1404–1410
Nadji M, Gomez-Ferenandez C, Ganjei-Azar P et al (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5, 993 breast cancers. Am J Clin Pathol 123:21–27
De Maeyer L, Van Limbergen E, De Nys K et al (2008) Does estrogen receptor-negative/progesterone receptor-positive breast carcinoma exist? J Clin Oncol 26:335–340
Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583
Rhodes A, Jasani B (2009) The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? J Clin Pathol 62:95–96
Rakha EA, El-Sayed ME, Green AR et al (2007) Biological and clinical characteristics of breast cancer with single hormone receptor-positive phenotype. J Clin Oncol 25:4772–4778
Hammond MEH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology / College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
Viale G, Regan MM, Maiorano E et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846–3652
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cserni, G., Francz, M., Kálmán, E. et al. Estrogen Receptor Negative and Progesterone Receptor Positive Breast Carcinomas—How Frequent are they?. Pathol. Oncol. Res. 17, 663–668 (2011). https://doi.org/10.1007/s12253-011-9366-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-011-9366-y